𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Gene therapy in The Netherlands: highlights from the Low Countries

✍ Scribed by Ellen A. M. Schenk-Braat; Leonie C. M. Kaptein; Marcella M. Hallemeesch; Chris H. Bangma; Rob C. Hoeben

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
135 KB
Volume
9
Category
Article
ISSN
1099-498X

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Gene therapy is an active research area in The Netherlands and Dutch scientists involved in fundamental and clinical gene therapy research significantly contribute to the progresses made in this field. This ranges from the establishment of the 293, 911 and PER.C6 cell lines, which are used worldwide for the production of replication‐defective adenoviral vectors, to the development of targeted viral vectors and T lymphocytes as well as of non‐viral vectors. Several milestones have been achieved in Dutch clinical gene therapy trials, including the first treatment worldwide of patients with adenosine deaminase deficiency with genetically corrected hematopoietic stem cells in collaboration with French and British scientists. Until now, about 230 patients with various diseases have been treated with viral and non‐viral gene therapy in this country. Ongoing and upcoming Dutch clinical trials focus on the translation of new developments in gene therapy research, including the restoration of genetic defects other than SCID, and the use of oncolytic adenoviruses and targeted T cells for the treatment of cancer. The growing commercial interest in Dutch clinical gene therapy is reflected by the involvement of two Dutch companies in ongoing trials as well as the participation of Dutch clinical centres in large phase III international multicenter immuno‐gene therapy trials on prostate cancer sponsored by an American company. Translational gene therapy research in The Netherlands is boosted at a governmental level by the Dutch Ministry of Health via a dedicated funding programme. This paper presents an overview on milestones in Dutch basic gene therapy research as well as on past, present and future clinical gene therapy trials in The Netherlands. Copyright Β© 2007 John Wiley & Sons, Ltd.

πŸ“œ SIMILAR VOLUMES

Gene therapy legislation in The Netherla
Gene therapy legislation in The Netherlands
✍ D. A. Bleijs; I. T. W. C. Haenen; J. E. N. Bergmans πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 105 KB

## Abstract Several regulatory organisations are involved in the assessment of clinical gene therapy trials involving genetically modified organisms (GMOs) in The Netherlands. Medical, ethical and scientific aspects are, for instance, evaluated by the Central Committee on Research Involving Human S

French gene therapy group reports on the
French gene therapy group reports on the adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID) : Position statement from the European Society of Gene Therapy (ESGT)
πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 42 KB

## Position statement from the European Society of Gene Therapy (ESGT) Background News of a serious adverse event in a clinical trial of gene therapy for inherited, X chromosome-linked Severe Combined Immunodeficiency (X-SCID) was made public on October 2, 2002, by the group of French scientists p

A splice junction mutation in intron 2 o
A splice junction mutation in intron 2 of the carbonic anhydrase II gene of osteopetrosis patients from Arabic countries
✍ Peiyi Y. Hu; Donna E. Roth; Laura A. Skaggs; Patrick J. Venta; Richard E. Tashia πŸ“‚ Article πŸ“… 1992 πŸ› John Wiley and Sons 🌐 English βš– 438 KB

Clinical manifestations in patients with carbonic anhydrase (CA) I1 deficiency include osteopetrosis, renal tubular acidosis, and cerebral calcification. Of the 39 reported cases of the carbonic anhydrase I1 deficiency syndrome, 72% were patients from North African and Middle Eastern countries, most